(ALNY) Alnylam Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US02043Q1076

RNA Interference, Therapeutics, Amyloidosis, Porphyria, Hypercholesterolemia

ALNY EPS (Earnings per Share)

EPS (Earnings per Share) of ALNY over the last years for every Quarter: "2020-03": -1.62, "2020-06": -1.56, "2020-09": -2.18, "2020-12": -2.09, "2021-03": -1.71, "2021-06": -1.61, "2021-09": -1.72, "2021-12": -2.16, "2022-03": -2, "2022-06": -2.29, "2022-09": -3.32, "2022-12": -1.68, "2023-03": -1.4, "2023-06": -2.21, "2023-09": 1.12, "2023-12": -1.1, "2024-03": -0.52, "2024-06": -0.13, "2024-09": -0.87, "2024-12": -0.65, "2025-03": -0.44,

ALNY Revenue

Revenue of ALNY over the last years for every Quarter: "2020-03": 99.476, "2020-06": 103.962, "2020-09": 125.853, "2020-12": 163.562, "2021-03": 177.566, "2021-06": 220.553, "2021-09": 187.633, "2021-12": 258.535, "2022-03": 213.259, "2022-06": 224.818, "2022-09": 264.306, "2022-12": 335.035, "2023-03": 319.29, "2023-06": 318.754, "2023-09": 750.53, "2023-12": 439.718, "2024-03": 494.333, "2024-06": 659.825, "2024-09": 500.919, "2024-12": 593.166, "2025-03": 594.189,

Description: ALNY Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biotechnology company that leverages RNA interference (RNAi) technology to develop and commercialize treatments for various diseases. The companys product portfolio includes approved therapies such as ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio, targeting conditions like hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.

The companys pipeline is robust, with multiple candidates in various stages of clinical development. Notable assets include vutrisiran, fitusiran, cemdisiran, and zilebesiran, which are being investigated for conditions such as transthyretin amyloidosis, hemophilia, myasthenia gravis, and hypertension. Alnylams partnerships with prominent pharmaceutical companies like Regeneron Pharmaceuticals, Roche Holding AG, and Sanofi S.A. underscore its commitment to advancing RNAi therapeutics.

From a technical analysis perspective, ALNYs stock has demonstrated a strong uptrend, with the last price at $306.09, above its 20-day, 50-day, and 200-day moving averages. The Average True Range (ATR) indicates moderate volatility, with a 3.51% daily price movement. Given the current technical setup, a potential price target could be $320-$330, based on the stocks momentum and the absence of significant resistance levels nearby.

Fundamentally, Alnylams market capitalization stands at approximately $37.8 billion, with a forward P/E ratio of 909.09, indicating high growth expectations. The companys return on equity (RoE) is negative, which is not uncommon for biotech firms with significant R&D investments. As the companys pipeline assets progress through clinical trials and potentially gain approval, the stocks valuation could be positively impacted. Assuming successful trial outcomes and subsequent commercialization, a potential long-term target for ALNY could be $400-$450, driven by the expected growth in revenue and earnings.

Combining technical and fundamental insights, a forecast for ALNY suggests potential short-term gains, driven by the stocks current momentum, and long-term growth, driven by the companys promising pipeline and partnerships. Investors should closely monitor clinical trial updates, regulatory decisions, and industry trends to adjust their investment strategies accordingly.

Additional Sources for ALNY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

ALNY Stock Overview

Market Cap in USD 41,977m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2004-05-28

ALNY Stock Ratings

Growth Rating 54.5
Fundamental -11.1
Dividend Rating 0.0
Rel. Strength 50.3
Analysts 4 of 5
Fair Price Momentum 309.19 USD
Fair Price DCF -

ALNY Dividends

Currently no dividends paid

ALNY Growth Ratios

Growth Correlation 3m 92.2%
Growth Correlation 12m 19.5%
Growth Correlation 5y 69.2%
CAGR 5y 16.84%
CAGR/Max DD 5y 0.40
Sharpe Ratio 12m -0.34
Alpha 19.04
Beta 1.019
Volatility 39.33%
Current Volume 733.7k
Average Volume 20d 698.8k
What is the price of ALNY shares?
As of July 01, 2025, the stock is trading at USD 326.09 with a total of 733,701 shares traded.
Over the past week, the price has changed by +4.14%, over one month by +6.53%, over three months by +20.77% and over the past year by +34.02%.
Is Alnylam Pharmaceuticals a good stock to buy?
Neither. Based on ValueRay´s Fundamental Analyses, Alnylam Pharmaceuticals is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -11.06 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALNY is around 309.19 USD . This means that ALNY is currently overvalued and has a potential downside of -5.18%.
Is ALNY a buy, sell or hold?
Alnylam Pharmaceuticals has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALNY.
  • Strong Buy: 12
  • Buy: 12
  • Hold: 7
  • Sell: 1
  • Strong Sell: 1
What are the forecasts for ALNY share price target?
According to our own proprietary Forecast Model, ALNY Alnylam Pharmaceuticals will be worth about 360.7 in July 2026. The stock is currently trading at 326.09. This means that the stock has a potential upside of +10.6%.
Issuer Target Up/Down from current
Wallstreet Target Price 323.6 -0.8%
Analysts Target Price 320.6 -1.7%
ValueRay Target Price 360.7 10.6%